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Abstract
Background: The discovery of a highly specific antibody against the aquaporin-4 (AQP4) water channel (AQP4-IgG)
unified the spectrum of neuromyelitis optica spectrum disorders (NMOSD), which are considered to be
antibody-mediated autoimmune diseases. The AQP4 water channel is located on astrocytic end-feet processes and
consists of six transmembrane helical domains forming three extracellular loops A, C, and E in which defined amino
acids were already proven to be critical for AQP4-IgG binding. However, the clinical relevance of these findings is
unclear. Therefore, we have characterized the epitope specificity of AQP4-IgG-positive NMOSD patients.
Methods: We established a cell-based flow cytometry assay for the quantitative detection of AQP4-IgG-positive
serum samples. Human embryonic kidney (HEK) cells were transiently transfected with an EmGFP-tagged
AQP4-M23, AQP4-M1, or six AQP4-M23 extracellular loop mutants including two mutations in loop A (serial AA
substitution, insertion of a myc-tag), two in loop C (N153Q, insertion of a myc-tag), and two in loop E (H230G,
insertion of a myc-tag). Fourty-seven baseline and 49 follow-up serum samples and six paired cerebrospinal fluid
(CSF) baseline samples of 47 AQP4-IgG-positive Austrian NMOSD patients were then tested for their binding
capability to AQP4-M1 and AQP4-M23 isoforms and these six extracellular loop mutants.
Results: Overall, we could identify two broad patterns of antibody recognition based on differential sensitivity to
mutations in extracellular loop A. Pattern A was characterized by reduced binding to the two mutations in loop A,
whereas pattern B had only partial or no reduced binding to these mutations. These two patterns were not
associated with significant differences in demographic and clinical parameters or serum titers in this retrospective
study. Interestingly, we found a change of AQP4-IgG epitope recognition pattern in seven of 20 NMOSD patients
with available follow-up samples. Moreover, we found different binding patterns in five of six paired CSF versus
serum samples, with a predominance of pattern A in CSF.
Conclusions: Our study demonstrates that AQP4-IgG in sera of NMOSD patients show distinct patterns of antibody
recognition. The clinical and diagnostic relevance of these findings have to be addressed in prospective studies.
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Background
Neuromyelitis optica (NMO) is a rare but devastating
autoimmune and demyelinating disease of the central
nervous system (CNS), usually characterized by optic
neuritis (ON) and/or longitudinally extensive transverse
myelitis (LETM) [1]. The discovery of a highly specific
autoantibody against the aquaporin-4 (AQP4) water
channel (AQP4-IgG) unified a spectrum of NMO-
related disorders and distinguished them from multiple
sclerosis (MS) [2]. In 2015, the International Panel for
NMO Diagnosis (IPND) revised the NMO diagnostic
criteria and defines the new nomenclature for the unify-
ing term NMO spectrum disorders (NMOSD) [3]. It was
shown that human AQP4-IgG enters the CNS through a
leaky blood-brain barrier (BBB) resulting from inflam-
mation and leads to a cascade of complement activation
and primary astrocytopathy followed by recruitment of
inflammatory cells, finally leading to oligodendrocyte in-
jury and demyelination [4–7]. The specific target antigen
is the AQP4 water channel located on astrocytic end-
feet processes, facing the blood-brain and brain-CSF in-
terfaces as well as on ependymal cells lining the ventri-
cles and on sensory organs such as retinal Müller cells
[8–10]. It consists of six transmembrane helical domains
and therefore forms three extracellular loops A, C, and
E in which defined amino acids (AA) were already
proven to be critical for AQP4-IgG binding [11–15].
However, the clinical relevance of these findings is still
unclear. There are two AQP4 isoforms, a long M1 iso-
form with translation initiation at Met-1 and a short
M23 isoform with translation initiation at Met-23 [16].
The M23 isoform aggregates in the membrane to or-
thogonal arrays of particles (OAPs) and was already
proven to have a higher AQP4-IgG binding specificity
than the M1 isoform [12, 15, 17–20]. Moreover, it has
been shown that the interaction between AQP4-IgG and
OAPs induces pathogenic mechanisms such as
complement-dependent cytotoxicity (CDC) and
antibody-dependent cellular cytotoxicity (ADCC) [21–
24]. Binding of AQP4-IgG to AQP4 OAPs was shown to
greatly increase CDC involving C1q binding to the IgG1
Fc region [25]. However, AQP4-IgG does not bind to
other OAP-forming aquaporins such as AQP0 and
AQPcic [12]. Therefore, it seems to be a combination of
specific AQP4 AA sequences leading to unique interac-
tions of the extracellular loops that evoke high binding
of AQP4-IgG and subsequent activation of an inflamma-
tory immune cascade. Early diagnosis and discrimination
from MS is very important since NMOSD cause severe
neurologic impairment and requires different and subse-
quent treatment. Therefore, the demand for AQP4-IgG
testing increased over the last decade and different as-
says for the detection of AQP4-IgG were developed in-
cluding cell-based assays using live or fixed cells, flow
cytometry, immunohistochemistry, and ELISA [26–30].
The aim of this study was to establish a sensitive and
specific cell-based flow cytometry assay for the detection
and quantification of serum AQP4-IgG antibodies.
Moreover, we aimed to characterize specific antibody
binding patterns to AQP4 epitopes in AQP4-IgG-
positive serum samples of NMOSD patients based on re-
cent findings by Owens et al. who identified specific
amino acid residues on AQP4 extracellular loops A, C,
and E as important epitopes for binding of human re-
combinant monoclonal AQP4 specific antibodies and
defined restricted binding patterns [14]. For the evalu-
ation of specific patterns of antigen recognition, we
tested 47 AQP4-IgG positive serum samples and 49
follow-up samples for their capability to bind AQP4-M1
and AQP4-M23 wild-type isoforms and six AQP4-M23
extracellular loop mutants. Additionally, we analyzed six
paired CSF samples that were collected at baseline.
Methods
Patients and serum samples
Serum samples for this retrospective case-control study
were collected in the Clinical Departments of Neurology
(Medical Universities of Innsbruck, Graz, and Vienna;
Austria) between 2005 and 2016 and stored at −20 °C
until use. Serum samples were obtained from 47 AQP4-
IgG-positive NMOSD patients (40 females and 7 males,
mean age 49 years, 95 % confidence interval (CI) 44–
54 years) diagnosed according to the international con-
sensus diagnostic criteria 2015 [3]. The AQP4-IgG ser-
ostatus of these patients was defined using a life
immunofluorescence cell-based assay for AQP4-M23
antibodies [18]. This assay was validated to be highly ac-
curate in the recently published European multicenter
study of AQP4-IgG assays in NMOSD [20]. NMOSD pa-
tients are part of an ongoing national epidemiological
study on NMOSD in Austria, and their clinical data
were described in detail before [18, 31]. We included 22
patients with clinically definite NMO (20 females, 2
males, mean age 50 years, 95 % CI 43–57 years), 14 pa-
tients with isolated LETM (11 females and 3 males,
mean age 57 years, 95 % CI 48–66 years), and 11 pa-
tients with isolated ON (9 females and 2 males, mean
age 37 years, 95 % CI 26–49 years). Fourteen patients
had an acute relapse (30 %). In addition to these 47
baseline samples, we also analyzed 49 follow-up samples
(mean follow-up 3.1 years, 95 % CI 1.9–4.4 years) from
20 patients (11 NMO, 4 LETM, 5 ON; 18 females, 2
males) and 6 paired baseline CSF samples from 5 NMO
and 1 ON patient (5 females and 1 male).
One hundred ninety-seven serum samples served as
controls for the establishment of the AQP4-IgG flow cy-
tometry assay. We included 68 patients with MS (44 fe-
male and 24 male, mean age 42 years, 95 % CI 40–
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44 years), 40 patients with other neurological diseases
(OND; 14 female and 26 male, mean age 54 years, 95 %
CI 48–60 years), and 89 healthy controls (HC; 39 female
and 50 male, median age 50 years, range 48–53 years).
Most of the patients have previously been included in
other studies on AQP4 autoantibodies [4, 18].
This study was approved by the ethical committee of
the Medical University of Innsbruck (study number
AM3041A), Medical University of Graz and Medical
University of Vienna. All patients, controls, or their legal
representatives gave written informed consent to the pa-
tient or proband consent form.
Mutagenesis of M23 AQP4
For the generation of all AQP4 mutants the vector con-
struct pcDNA6.2 (M23) AQP4-EmGFP was used [18].
Both myc-tags and a 4-amino acid serial substitution as
well as point mutations were introduced into the AQP4
extracellular loops using Quickchange II Site-Directed
Mutagenesis Kit (Agilent, #200521). Vector constructs
and primers were designed using Vector NTI Advance
Software (Invitrogen) according to the instructions for
the Quickchange II Site-Directed Mutagenesis Kit. All
primers were made by custom oligonucleotide synthesis
from Microsynth and are shown in Additional file 1. All
constructs were fully sequenced (Microsynth). All muta-
tions are shown in Table 1 and Fig. 1.
Myc-tag
To change the conformation of the extracellular loops
A, C, and E, a 10-amino acid long myc sequence (H-
Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu-OH) was in-
troduced at position G60 of extracellular loop A (mycA),
at position V141 of extracellular loop C (mycC) and at
position G225 of extracellular loop E (mycE) based on
previous studies [14, 32].
Single point and serial substitutions
Extracellular loops A, C, and E of AQP4-M23 were mu-
tated by site-directed mutagenesis as described before
[14]. A serial substitution in the extracellular loop A re-
placed the amino acid sequence 66LPVD69 by four ala-
nine residues (delA3). Furthermore, a single point
mutation in extracellular loop C replaced asparagine
with glutamine (N153Q) and in the extracellular loop E,
histidine was replaced by glycine (H230G). Mutations
were chosen based on previous studies [13, 14].
AQP4-IgG cell-based flow cytometry assay
Human embryonic kidney cells HEK-293A (ATCC, LGC
Standards GmbH) were seeded in 3 ml of DMEM
medium supplemented with 4.5 g/l glucose (Invitrogen
Life Technologies, #41965-039), 1 % non essential amino
acid (NEAA, Invitrogen #11140-035), 200 mM L-
glutamine (Invitrogen #11140-035) and 10 % fetal calf
serum (FCS, Invitrogen #10270) in 6-well plates (TPP
Switzerland, #92006) at a density of 4 × 105 cells per
well. Approximately 24 h later, cells were transiently
transfected with the plasmids encoding AQP4-M1,
AQP4-M23 [18], or AQP4-M23 mutations (delA3,
N153Q, H230G, mycA, mycC, mycE), respectively. All
resulting proteins are C-terminally fused to EmGFP.
Seventy-two hours post transfection the cells were har-
vested. Therefore, the medium was removed and cells
washed with 3 ml PBS (Sigma, #P3813). Cell layer was
detached using 150 μl of 0.05 % trypsin-EDTA (Invitro-
gen, #25300-054). Trypsinization was stopped by adding
1 ml medium to the cells, and the suspension was trans-
ferred to a 50-ml falcon tube and centrifuged at 500×g
for 5 min at room temperature (RT). After removing the
supernatant, the cell pellet was resuspended in 10 ml
FACS buffer (PBS + 10 % FCS + 1 mM EDTA) supple-
mented with FcR Blocking Reagent (Milteny, #130-059-
901) and blocked for 1 h by shaking carefully at 4 °C.
Meanwhile, serum dilutions were prepared. Each serum
sample was diluted 1:10 in 100 μl FACS buffer. Serum
was plated on a round-bottom 96-well plate (TPP
Switzerland, #92096), 100 μl of serum dilution per well,
and duplicates were used for all samples. After blocking,
cells were centrifuged (500×g, 5 min) and the cell pellet
was resuspended in FACS buffer. Approximately
150,000–200,000 cells in 100 μl FACS buffer were added
to the serum dilutions (reaching the final serum dilution
of 1:20) in each well. Cell/serum mixture was in incu-
bated for 30 min by shaking carefully at 4 °C. Subse-
quently, cells were washed with FACS buffer by
centrifugation for 5 min at 500 x g and decanting the
supernatant carefully. Cells were incubated for 30 min
with secondary antibody goat anti-human IgG, Fc (Dia-
nova, #109-135-098) 1:100 dilution by shaking at 4 °C.
Finally, cells were fixed in 100 μl FACS buffer supple-
mented with 10 μl CellFIX (BD Biosciences, #340181).
AQP4-IgG binding was determined by using the BD
AccuriTm C6 flow cytometer and the BD AccuriTm C6
software (BD Biosciences). Precision was determined by
running all samples in duplicates in order to calculate
the intra-assay variability. Samples we replicated in trip-
licates if the coefficient of variation was higher than
Table 1 Extracellular loop mutations
Loops Name WT sequence Mutated sequence
A AQP4-delA3 66LPVD69 66AAAA69
A AQP4-mycA 59WGGT62 59WG-myc-GT62
C AQP4-N153Q 150VHGNLT155 150VHGQLT155
C AQP4-mycC 140SVVG143 140SV-myc-VG143
E AQP4-H230G 228ENHW231 228ENGW231
E AQP4-mycE 226NWEN229 226myc-NWEN229
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15 %. AQP4 and AQP4-mutant expressing cells were de-
tected in the green FL-1 channel and the antibody bind-
ing was measured in the red FL-4 channel to avoid
spectral overlapping. A minimum of 10,000 EmGFPpos
cells were acquired for each sample. For binding analysis
gates were set on the cells with an emGFP expression
level of FL-1 104 and 105 for AQP4pos population as re-
cently described for a comparable FACS autoantibody
assay [33]. The AQP4neg population was gated on FL-1
< 104 (Additional file 2). The median fluorescence inten-
sity (MFI) in the FL-4 channel was obtained by gating
on the AQP4pos and AQP4neg populations. The binding
ratio was calculated as MFI(AQP4pos)/MFI(AQP4neg).
Cells transfected with the mutants and with AQP4-M23
WT were always measured together in the same experi-
ment to determine the binding percentage as percent
binding = MFI mutant AQP4posð Þ−MFI mutant AQP4negð ÞMFI WT AQP4posð Þ−MFI WT AQP4negð Þ  100%.
Recombinant AQP4-specific monoclonal antibodies
Recombinant monoclonal AQP4-specific antibodies
(AQP4 rAbs (kindly provided by Prof. Jeffrey L. Bennett
from the University of Colorado, Denver, CO) were gen-
erated from clonally expanded cerebrospinal fluid (CSF)
plasma blasts as described previously [5]. For binding
specificities of human AQP4 rAbs to AQP4-M1 and
AQP4-M23 isoforms cell-based flow cytometry assay
was performed as described before. Briefly, 1 μg of each
AQP4 rAb was diluted in 50 μl FACS buffer and plated
on a round-bottom 96-well plate. To the rAb dilutions
(reaching a final dilution of 1 μg/100 μl (10 μg/ml)) in
each well, 150,000–200,000 cells in 50 μl FACS buffer
were added. All samples were run in duplicates. For de-
termination of binding, constants of AQP4 rAbs to
AQP4-M23 Abs were diluted from 100 to 0.8 μg/ml and
measured by cell-based flow cytometry assay described
before.
Blue native gel electrophoresis
All AQP4 mutant constructs were studied for OAP as-
sembly by using blue native gel electrophoresis (BN-
PAGE). Therefore, HEK-293A cells were transfected as
described before. Cells were lysed in 1X NativePageTM
Sample Buffer (Invitrogen, # BN2003) supplemented
with 500 mM 6-aminohexanoic acid, 1 % Triton X-100
and protease inhibitor cocktail, incubated for 30 min on
ice and centrifuged at 22,000×g for 30 min. Supernatants
were supplemented with NativePageTM 5 % G-250 (Invi-
trogen, #BN2004) and loaded to NativePAGE™ Novex™
3-12 % Bis-Tris Protein Gels (Invitrogen, # BN1001).
The running buffers were prepared according to the
manufacturer’s protocol. Proteins were blotted onto
polyvinylidene difluoride (PVDF) membrane using
NuPage Transfer Buffer (Invitrogen, #NP0006). For
Fig. 1 Schematic model of mutations performed in AQP4 extracellular loops. AQP4 schematic showing the positions of mutations introduced
into the extracellular domains. Original amino acids (orange), amino acid substitutions (green), and the inserted myc sequence (red)
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immunoblot analysis, proteins were fixed for 15 min in
8 % acetic acid and membranes were blocked in 1 %
Amersham ECL Prime Blocking Reagent (GE Health-
care, # RPN418) diluted in 0.1 % PBS-Tween. Primary
rabbit anti-AQP4 antibody (Sigma, # A5971) was incu-
bated at 4 °C overnight. Secondary antibody Amersham
ECL Rabbit IgG (GE Healthcare, # Na934) was incu-
bated at RT for 1 h. Labeled proteins were detected
using the WesternBright ECL (Biozym, # 541004) and
visualized on the Fusion FX7 Vilber Lourmat imaging
system.
Statistical analysis
Statistical analysis was done using IBM SPSS software
(release 22.0, IBM) or GraphPad Prism 6 (GraphPad).
Between-group comparisons were performed with
ANOVA or Kruskal-Wallis test, T test or Mann-Whitney
U test, Fisher’s exact test, and chi-square test. Correl-
ation of parameters was analyzed with Spearman’s non-
parametric correlation. Receiver operating characteristic
(ROC) curve analysis was used to determine cutoff
FACS binding ratios and immunological parameters de-
termining antibody binding patterns. The effect of
demographic and clinical parameters on binding pat-
terns was analyzed using binary logistic regression ana-
lysis. Heatmaps were drawn using GENE-E matrix
visualization and analysis software (http://www.broadin-
stitute.org/cancer/software/GENE-E/index.html). Statis-
tical significance was defined as two-sided p value <0.05
and Bonferroni corrections were applied for multiple
comparisons when appropriate.
Results
Establishment of a flow cytometry based detection
method for AQP4-IgG autoantibodies
We established a cell-based flow cytometry assay as de-
tection method for AQP4-antibodies and screened 47
AQP4-IgG positive baseline serum samples of 47
NMOSD patients and 197 AQP4-IgG negative control
serum samples for their binding ratio against the AQP4-
M23 isoform expressed on HEK-293A cells (Fig. 2).
HEK-293A cells with the fluorescence intensity of 104–
105 were gated to determine the binding ratio to the
transfected cell population and to ensure a high and
comparable expression level between the transfectants
(Additional file 2). A cutoff value (1.323) was calculated
by the binding ratio of our seronegative control groups
using ROC analysis. Serum positivity of AQP4 autoanti-
bodies was confirmed in all NMOSD samples whereas
none of the controls was seropositive, yielding an assay
sensitivity and specificity of 100 % (95 % CI 92–100 %
and 95 % CI 98–100 %, respectively).
Fig. 2 AQP4-M23 binding ratios in seropositive NMOSD patients and seronegative control groups. AQP4-IgGs were exclusively detected in serum samples
of patients with NMOSD, but not in MS patients, patients with OND or HC. The cutoff value of 1.323 is indicated by a dashed horizontal line. Medians are
indicated by horizontal bars. Binding ratios were compared by using a non-parametric test (Kruskal-Wallis Test) revealing p< 0.0001. NMOSD neuromyelitis
optica spectrum disorders, MSmultiple sclerosis, OND other neurological diseases, HC healthy controls
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Moreover, we validated our AQP4-IgG assay using hu-
man monoclonal antibodies derived from clonally ex-
panded CSF plasmablasts of AQP4-IgG positive
NMOSD patients [17]. Additional file 3A shows binding
curves of five recombinant monoclonal antibodies tested
for their binding affinities to the AQP4-M23 isoform
expressed in HEK-293A cells by flow cytometry.
Heterogeneous AQP4-IgG binding to AQP4 isoforms and
extracellular loop mutants in NMOSD serum samples
As previous studies showed that AQP4-IgGs recognize
distinct conformational epitopes on AQP4 we generated
six extracellular loop mutants. The serial AA substitu-
tion in loop A (delA3) and a single AA substitution in
loop C (N153Q) and loop E (H230G) were already tested
for their impact on binding of monoclonal rAbs de-
scribed previously [14]. However, antibody recognition
studies of heavily manipulated AQP4 loops by insertion
of the myc epitope have to our knowledge not been
reported.
As seen in Table 2, we found a reduced antibody bind-
ing capability to all mutations in 47 AQP4-IgG positive
baseline serum samples. The strongest impact on anti-
body binding was observed in the mycE mutation with a
binding capability of 5.4 % (95 % CI 3.7–7.1) compared
to AQP4-M23, followed by the mycC mutation with
13.1 % (95 % CI 9.3–16.9) and the mycA mutation with
38.1 % (95 % CI 29.0–47.4). This reduction of antibody
binding is also seen for AQP4-IgG binding ratios
(Table 2). To confirm surface localization of the myc
epitope, live cell immunofluorescence stainings were
performed using an anti-myc antibody. Myc epitopes of
loop A and loop C showed typical surface stainings,
whereas loop E could not be detected on the surface.
However, after fixation intracellular expression was
confirmed.
In contrast to loops containing myc epitopes, single
point mutations showed less influence on antibody bind-
ing in the case of H230G (36.3 %, 95 % CI 29.6–43.0)
and N153Q (67.3 %, 95 % CI 56.9–77.8). However, in
loop A the delA3 substitution presented with a mean
binding of 40.9 % (95 % CI 32.0–49.8), which is compar-
able to the result of mycA. As seen in Table 2, both the
binding ratio and the range of percent binding varied
considerably in every investigated mutation or the
AQP4-M1 isoform.
Finally, we analyzed the role of OAP formation in the
observed reduced antibody binding. Whereas the three
point mutations and the myc-tag in loop A did not affect
OAP assembly, introduced myc-tags in loops C and E
caused OAP disruption as distinct tetramers and higher
order arrays are absent when visualized by BN-PAGE
(Additional file 4).
Mutagenesis of AQP4 extracellular loop A identifies two
broad patterns of serum AQP4-IgG recognition
Consistent with a recent publication on AQP4-specific
rAbs recognizing restricted binding patterns [14], we
also identified two broad binding patterns for serum
antibody recognition comprising a mainly loop A-
dependent pattern A and a loop A-independent pattern
B using the unbiased approach of hierarchical clustering
(Fig. 3 and Table 3). We also tested five monoclonal
rAbs for their binding capability to both loop A muta-
tions and could confirm the results by Owens et al. who
identified rAbs ON09-3 #33 and ON07-5 #58 as loop A-
dependent (Additional file 3B) [14].
Thirty-seven (79 %) of our AQP4-IgG positive serum
samples showed reduced binding to both loop A muta-
tions (Fig. 3 and Table 3) confirming that most of our
NMOSD sera required the intact extracellular loop A se-
quence. Using ROC analysis, we determined that pattern
A AQP4-IgG positive samples were characterized by re-
duced binding to the delA3 mutant (cutoff <58 %) and
the mycA mutant (cutoff <66 %). Importantly, AQP4-
M23 binding ratios did not influence binding patterns,
whereas reduced binding ratios for the delA3 mutant
(cutoff <3.4) and the mycA mutant (cutoff <3.7) were
significantly associated with pattern A. Moreover, we
were able to verify these binding patterns by analyzing
the absolute loss of binding (binding ratios) of AQP4
isoforms and mutants (Additional file 5) and by using 49
Table 2 Antibody binding of 47 AQP4-IgG-positive baseline serum samples to AQP4-M23, AQP4-M1 and AQP4-M23 mutants
AQP4-IgG binding ratio (mean, 95 % CI) AQP4-IgG binding in % of AQP4-M23 (mean, 95 % CI)
AQP4-M23 isoform 4.84 (3.98–5.70) Reference (100 %)
AQP4-M1 isoform 1.48 (1.11–1.86) 25.83 (20.19–31.47)
AQP4-mycA (loop A) 2.74 (2.17–3.31) 38.15 (28.95–47.35)
AQP4-delA3 (loop A) 2.85 (2.26–3.44) 40.91 (31.99–49.82)
AQP4-mycC (loop C) 1.49 (1.38–1.60) 13.12 (9.34–16.90)
AQP4-N153Q (loop C) 3.88 (3.26–4.50) 67.35 (56.88–77.81)
AQP4-mycE (loop E) 1.17 (1.12–1.23) 5.39 (3.69–7.08)
AQP4-H230G (loop E) 2.69 (2.12–3.25) 36.28 (29.62–42.95)
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Fig. 3 (See legend on next page.)
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follow-up samples as a validation cohort (Additional file
6).
Both patterns were recognized by AQP4-IgG autoanti-
bodies in the serum of patients with all three different
clinical NMOSD entities: NMO, LETM, and ON. In this
small cohort of NMOSD patients, the loop A-
independent pattern B was more often found in patients
with clinically definite NMO (8/10 versus 14/37, Table 4).
Furthermore, pattern B was more often found in patients
suffering from an acute relapse. But neither these nor
other differences regarding sex, age, age at disease onset,
disease duration, number of relapses, disability (EDSS),
or treatment reached statistical significance.
In addition to the 47 baseline samples, we have also ana-
lyzed 49 follow-up samples from 20 patients. Thirteen pa-
tients (12 females, 1 male; 6 NMO, 4 LETM, 3 ON)
showed stable antibody binding pattern (12 with pattern
A and 1 with pattern B), and seven patients (6 females, 1
male; 5 NMO, 2 ON) showed a change in antibody bind-
ing patterns (Fig. 4). Two patients showed a change from
pattern A→ B and five patients showed a change from
pattern B→A. The recognition pattern changes of all
follow-up samples and their relation to absolute antibody
binding values, disease duration, presence of acute relapse,
and therapies are shown in Fig. 4. There was no obvious
association with the presence of relapses (5/29 in the
group with no changes and 5/29 in the group with
changes), specific treatments, or treatment changes. How-
ever, the clinical relevance of these observations needs to
be analyzed in a larger prospective study.
Different patterns of AQP4-IgG recognition in CSF and
serum samples
Finally, we had the chance to analyze six paired CSF and
serum samples taken at baseline. Surprisingly, we found
different binding patterns in the CSF versus serum sam-
ples that were taken at the same time point in five of six
patients (Fig. 5). Whereas all CSF AQP4-IgG antibodies
had a loop A-dependent pattern A, five of six serum
antibodies had a loop A-independent pattern B. The
clinical, CSF, and demographic characteristics of these
six NMOSD patients are shown in Table 5.
Discussion
In this study, we analyzed defined epitopes in the extra-
cellular loops of AQP4 recognized by AQP4-IgG positive
(See figure on previous page.)
Fig. 3 Heatmap of serum AQP4-antibody levels against AQP4-M23, AQP4-M1 and AQP4-M23 mutants (columns) at baseline. Rows are individual samples
with patient IDs (Nr) and flow cytometry AQP4-M23 binding ratios (BR) shown at the right side. Data are shown as percent binding of AQP4-M23. Values
range from blue (0 %) to white (50 %) to red (100 %). Columns were clustered according to their Pearson’s correlation coefficients, and rows were clustered
according to their Eucledian distance (both average linkage). Two major antibody binding patterns were identified, a loop A-dependent pattern A (upper
panel) and an independent pattern B. The heatmap was generated using GENE-E matrix visualization and analysis
software (http://www.broadinstitute.org/cancer/software/GENE-E/index.html)
Table 3 Immunological correlates of AQP4-IgG binding patterns
Loop A-dependent pattern A (n = 37) Loop A-independent pattern B (n = 10) Area under the curve (95 % CI) p value*
AQP-M23 binding 4.52 (3.57–5.48) 6.02 (3.86–8.19) 0.50 (0.25–0.75) 0.999
AQP4-M1 binding 1.42 (1.01–1.83) 1.78 (0.59–2.97) 0.56 (0.33–0.78) 0.999
AQP4-M1 (% M23) 25.1 (19.3–31.1) 28.1 (10.0–31.5) 0.78 (0.59–0.97) 0.405
AQP4-mycA binding 1.95 (1.69–2.21) 5.66 (4.12–7.19) 0.99 (0.96–1.00) <0.001
AQP4-mycA (% M23) 24.5 (18.5–30.52) 88.6 (80.4–96.8) 1.00 (1.00) <0.001
AQP4-delA3 binding 2.15 (1.75–2.56) 5.42 (3.77–7.07) 0.96 (0.90–1.00) <0.001
AQP4-delA3 (% M23) 28.7 (21.9–35.5) 86.2 (77.0–95.4) 0.97 (0.92–1.00) <0.001
AQP4-mycC binding 1.36 (1.32–1.41) 1.49 (1.38–1.60) 0.88 (0.72–1.00) 0.045
AQP4-mycC (% M23) 11.1 (7.4–14.8) 20.6 (8.7–32.5) 0.72 (0.52–0. 93) 0.999
AQP4-N153Q binding 3.47 (2.86–4.07) 5.42 (3.63–7.20) 0.75 (0.58–0.92) 0.750
AQP4-N153Q (% M23) 61.3 (49.1–73.5) 89.6 (74.2–100) 0.72 (0.55–0.89) 0.999
AQP4-mycE binding 1.14 (1.11–1.17) 1.29 (1.05–1.53) 0.63 (0.33–0.92) 0.999
AQP4-mycE (% M23) 5.8 (3.7–7.9) 3.7 (2.0–5.5) 0.54 (0.36–0.71) 0.999
AQP4-H230G binding 2.35 (1.80–2.89) 3.94 (2.22–5.67) 0.71 (0.52–0.91) 0.999
AQP4-H230G (% M23) 31.3 (25.0–38.2) 53.6 (35.7–71.4) 0.74 (0.59–0.90) 0.870
AQP4-M23, AQP4-M1, and extracellular loop A, C, and E mutations were expressed in HEK-293A cells and assayed to categorize pattern A and pattern B serum
samples as indicated in Fig. 3. Data are shown as means with 95 % confidence interval. Binding binding ratios
*The area under the curve was analyzed by receiver operator curve (ROC) analysis and p values were corrected for 15 comparisons
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serum and CSF samples of 47 NMOSD patients. Overall,
we found reduced binding to all mutations and AQP4-
M1 compared to the AQP4-M23 isoform and distin-
guished two broad patterns of AQP4-IgG recognition, a
loop A-dependent pattern A and a loop A-independent
pattern B. Further, we observed reduced binding to mul-
tiple AQP4 mutants in the majority of all NMOSD pa-
tients indicating that the human AQP4 antibody
response is defined by multiple epitopes. These findings
are consistent with previous studies showing that serum
autoantibodies bind to multiple targets including AQP4
peptides, monomers, and higher order arrays [15, 34]. A
comparable study on conformational epitopes of the
myelin oligodendrocyte glycoprotein (MOG) could show
that the immune response can be directed against one
single or multiple epitopes [33].
Introduction of a myc-tag in the extracellular loops
A, C, and E reduced the recognition of AQP4 to
38.2 % (range 29.0–47.4 %), 13.1 % (range 9.3–
16.9 %), and 5.4 % (range 3.7–7.1 %), respectively, in-
dicating that elongation of the extracellular loop se-
quences caused serious conformational changes with
great impact on antibody recognition. AA G60 in
loop A was previously reported as less critical for
AQP4-IgG binding and therefore selected for inser-
tion of the myc-tag sequence [14]. As we could
demonstrate by BN-PAGE, introduction of the myc-
tag did not affect OAP assembly and caused minor
reduction in antibody binding (38.2 %, 95 % CI 29.0–
47.4; binding ratio 2.7, 95 % CI 2.2–3.3). However,
the observed decrease in antibody recognition of 37
of 47 baseline serum samples indicates either the loss
of specific loop A epitopes by the myc insertion or
its influence on the conformation of nearby loops
within the tetramer structure.
In contrast to the mycA mutation, both mycC and
mycE mutations exhibited loss of OAP formation and
a dramatic reduction of antibody recognition. The
position for the myc-tag insertion into the extracellu-
lar loop C was based on previous studies by Crane et
al. who demonstrated that position V141 did not
affect AQP4 assembly into OAPs when transfected
into COS-7 cells [32, 35]. In contrast to this study,
we could not detect OAP formation when transfect-
ing HEK-293A cells with the mycC mutant construct
and detected major reduction in antibody recognition
(13.1 %, 95 % CI 9.3–16.9; binding ration 1.5, 95 %
CI 1.4–1.6). The position H230 in loop E was chosen
by the study by Owens et al. who demonstrated
minor impact in rAb binding [14]. However, we
proved the mycE mutant to cause OAP disruption
and consequently detected highly impaired AQP4-IgG
Table 4 Clinical and demographic characteristics of NMOSD patients according to AQP4-IgG binding pattern at baseline
Loop A-dependent pattern A (n = 37) Loop A-independent pattern B (n = 10) p value
Femalesa 31 (84 %) 9 (90 %) 0.125
Age (years)b 49.3 (43.6-55.1) 49.0 (36.1-62.0) 0.764
Age at onset (years)b 41.1 (35.2-47.1) 42.8 (26.3-59.2) 0.722
Disease duration (years)b 8.6 (6.4-10.9) 6.8 (0–13.9) 0.662
Acute relapsea 8 (22 %) 6 (60 %) 0.550
EDSSc 3 (0.5-8.5) 5 (2–7) 0.196
Relapsesc 3 (1–19) 3 (1–11) 0.109
Diagnosisa
NMO 14 (38 %) 8 (80 %) 0.455
LETM 14 (38 %) 0 (0 %)
ON 9 (24 %) 2 (20 %)
Treatmentd




Other treatments 4 2
AQP4-M23, AQP4-M1 and extracellular loop A, C, and E mutations were expressed in HEK-293A cells and assayed to categorize pattern A and pattern B serum
samples as indicated in Fig. 3. Other treatments = interferon-ß (1), cyclophosphamide (1), mitoxanthrone (1), intravenous immunoglobulins (2) and plasma
exchange (1). The effect of demographic and clinical parameters on binding patterns was statistically analyzed using binary logistic regression analysis
aNumber of cases (%)
bMean (95 % confidence interval)
cMedian (range)
dNumber of cases
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binding (5.4 %, 95 % CI 3.7–7.1; binding ratio 1.2,
95 % CI 1.1–1.2).
As disruption of OAP formation in both mycC and
mycE mutants severely decreases the binding capability
of all serum samples, we could not find significant differ-
ences between the analyzed serum samples. The physio-
logical role of AQP4 OAPs is still unknown but these
aggregates were already proven to have a higher AQP4-
IgG binding specificity [12, 17–19]. Moreover, it was
shown that AQP4-IgG CDC is dependent on OAP as-
sembly [36]. Interestingly, other OAP-forming AQP4
proteins, such as the lens AQP-0 and the insect AQP-
cic, were not recognized by AQP4-IgG, suggesting that
defined epitopes have key functions in antibody recogni-
tion [12, 37]. In summary, our study suggests that as-
sembly into OAPs appears to be a key factor for binding
of AQP4-IgG as our serum samples did not only show a
significant reduction in binding to the non-OAP-
forming AQP4-M1 isoform but also to the non-OAP-
forming mycC and mycE mutant constructs.
In contrast, single point mutations N153Q (loop C)
and H230G (loop E) did not disrupt OAP formation but
also caused reduced binding of AQP4-IgG. However, im-
pact on antibody binding was not as pronounced, result-
ing in slightly reduced binding to the N153Q mutation
in loop C (67.4 %, 95 % Cl 56.9–77.8, binding ratio 3.9,
95 % CI 3.3–4.5) and the H230G mutation in loop E
(36.3 %, 95 % Cl 29.6–43.0, binding ratio 2.7, 95 % CI
2.2–3.3) compared to AQP4-M23 WT (100 % reference,
binding ratio 4.8, 95 % CI 4.0–5.7). Although these
single mutations were shown to have a remarkable
role in antibody recognition as they significantly re-
duced binding of all rAbs [14], we detected only
minor reductions compared to the myc-tag mutants,
indicating that most of the serum samples analyzed
are polyclonal in nature and therefore bind to differ-
ent epitopes on the AQP4 protein.
Overall, we identified two broad binding patterns for
serum antibody recognition comprising a mainly loop
Fig. 4 Heatmap of serum AQP4-antibody levels against AQP4-M23,
AQP4-M1 and AQP4-M23 mutants (columns) in baseline and follow-up
samples of 20 NMOSD patients with follow-up samples. Rows are
individual samples with patient IDs (Nr), flow cytometry AQP4-M23
binding ratios (BR), AQP4-IgG binding patterns (BP), disease duration in
years (DD), presence of acute relapses (Rel), and therapies (Ther) shown
at the right side. Data are shown as percent binding of AQP4-M23. Values
range from blue (0 %) to white (50 %) to red (100 %). Columns were
clustered according to their Pearson’s correlation coefficients. Two major
antibody binding patterns were identified, a loop A-dependent pattern
A and an independent pattern B. The heatmap was generated using
GENE-E matrix visualization and analysis software (http://www.
broadinstitute.org/cancer/software/GENE-E/index.html). AZA azathioprine,
NoTh no therapy, other other immunsuppressive therapies, PLEX plasma
exchange, Pred _ corticosteroids, RTX rituximab
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A-dependent pattern A in 37 of 47 serum samples,
based on the serial AA substitution delA3 and the
mycA mutation, and a loop A-independent pattern B
in 10 of 47 serum samples that showed a broader
recognition pattern. This fits well to the data of Ow-
ens et al. who could also categorize rAbs into loop
A-dependent and loop A-independent patterns [14].
The serial AA substitution in loop A (delA3) had a
comparable impact on AQP4-IgG binding (40.9 %,
range 32.0–49.8 %; binding ratio 2.9, 95 % CI 2.3–
3.4) as the mycA mutation (38.2 %, range 29.0–
47.4 %; binding ratio 2.7, 95 % CI 2.2–3.3). Similar
findings were previously reported by Pisani et al. who
detected a reduced binding in five of eleven NMO
sera to a serial AA deletion at a different position in
the extracellular loop A [12]. Furthermore, the delA3
include the substitution at Asp69 that have been pre-
viously reported as the most sensitive residue in the
extracellular loop A as it impaired AQP4-IgG binding
in 93 % of NMO patient sera [13] and produced a
significant loss of binding for all loop A-dependent
rAbs [14]. These defined binding patterns recognized
by NMOSD patients with different disease entities
(NMO, LETM, ON) did not reveal any statistically
significant association between epitope recognition
and disease phenotype. Analysis during the course of
disease revealed a change of AQP4-IgG epitope rec-
ognition in 7/20 NMOSD patients with long-term
persistence of AQP4-IgG. These patients had a
change from a loop A-dependent pattern A to a loop
A-independent pattern B (5 cases) or vice versa (2
cases) during their disease course. In contrast, in a
previous study on patients with anti-MOG antibodies,
the recognized epitopes remained constant in nine of
nine analyzed cases [33]. However, we did not ob-
serve any significant association between a change in
the pattern and acute relapses, a change in treatment,
or a specific treatment such as B cell depletion.
Fig. 5 Heatmap of CSF and serum AQP4-antibody levels against AQP4-M23, AQP4-M1, and AQP4-M23 mutants (columns) in baseline samples of 6
NMOSD patients with paired CSF and serum samples. Rows are individual samples with patient IDs (Nr), flow cytometry AQP4-M23 binding
ratios (BR), and AQP4-IgG binding patterns (BP) shown at the right side. Data are shown as percent binding of AQP4-M23. Values range from blue
(0 %) to white (50 %) to red (100 %). Columns were clustered according to their Pearson’s correlation coefficients and rows were cluster according
to their Eucledian distance (both average linkage). Two major antibody binding patterns were identified, a loop A-dependent pattern A and an
independent pattern B. Five of the six patients had different antibody recognition patterns in CSF and serum. The heatmap was generated using
GENE-E matrix visualization and analysis software (http://www.broadinstitute.org/cancer/software/GENE-E/index.html)
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Interestingly, we found different binding patterns in
the CSF versus serum compartment in five out of six
NMOSD patients. CSF and serum samples were taken
at the same time point and analyzed for their binding
capability to each mutation. We detected a loop A-
dependent pattern A in all six CSF samples versus a
loop A-independent pattern B in five of six serum
samples suggesting a restricted intrathecal AQP4 epi-
tope recognition. Previous findings suggested that
these antibodies are mainly produced in the periphery
[38, 39] but it becomes more and more evident that
intrathecal AQP4 specific B cells and their corre-
sponding plasma cells might also be a source of
AQP4 specific CNS antibodies [5, 40].
Finally, our study might also help to explain the
differences between sensitivities of immunoassays
used for the measurement of AQP4-IgG antibodies
and cell-based assays, which can detect antibodies to
all AQP4 epitopes being the most sensitive assays
[27, 29].
Our study has the following limitations: (1) we have
analyzed only a small proportion of all potential immu-
nodominant epitopes recognized by NMOSD patients
and since OAP disrupting mutants do not make a con-
tribution to separation into specific binding patterns, fu-
ture studies should focus on mutations that do not
affect OAP assembly. A systematical epitope analysis as
it was performed with human rAbs [14] might identify
defined amino acids and specific epitopes. (2) As this
was a retrospective case-control study, we cannot make
any definite conclusion on the clinical relevance of our
findings. Therefore, the clinical and diagnostic relevance
of our findings have to be addressed in prospective
studies.
Conclusions
In conclusion, the AQP4-IgG immune response of our
NMOSD cohort was directed against multiple epitopes
of AQP4 in all analyzed serum samples, reflecting the
heterogeneous properties of these autoantibodies.
NMOSD sera showed two broad patterns of epitope rec-
ognition, a loop A-dependent pattern A and a loop A-
independent pattern B. These patterns further revealed a
change of AQP4-IgG epitope recognition during the
course of disease in at least some of our NMOSD pa-
tients. Finally, different patterns in the serum versus CSF
compartment suggest restricted intrathecal AQP4-IgG
recognition in five out of six patients. Our results pro-
vide strong evidence that serum AQP4-IgGs are
dependent on both defined extracellular epitopes and
conformational arrangement.
Table 5 Clinical, CSF, and demographic characteristics of NMOSD patients with available paired CSF and serum samples
Patient number 29 38 44 45 46 47
Sex Female Female Female Female Female Male
Age (y) 73.7 52.4 41.4 50.1 28.3 68.9
Age at onset (y) 73.7 52.2 26.4 49.6 25.6 68.9
Disease duration (y) 0.00 0.21 14.90 0.50 2.72 0.01
Diagnosis NMO ON NMO NMO NMO NMO
Acute relapse yes yes yes yes yes no
Number of relapses 1 1 5 2 6 1
EDSS 2.0 2.0 6.5 2.5 6.0 5.5
Treatment NoTh Pred RTX AZA RTX PLEX
CSF cells/μl 9 4 5 1 4 73
Albumin quotient 6.59 3.97 6.20 8.92 2.32 18.12
IgG index 0.64 0.55 0.48 0.58 1.20 0.58
CSF OCB Negative Negative Negative Negative Positive Negative
AQP4-IgG CSFa 6.19 1.23 4.18 2.50 5.04 4.15
AQP4-IgG seruma 11.59 3.38 15.02 4.47 9.38 7.98
AQP4-IgG quotient 0.53 0.36 0.28 0.56 0.54 0.52
AQP4-IgG pattern CSF A A A A A A
AQP4-IgG pattern serum B B A B B B
AQP4-M23, AQP4-M1 and extracellular loop A, C, and E mutations were expressed in HEK-293A cells and assayed to categorize pattern A and pattern B serum
samples as indicated in Fig. 3
AZA azathioprine, NoTh no therapy, PLEX plasma exchange, Pred corticosteroids, RTX rituximab, y years, albumin quotient CSF albumin/serum albumin, IgG index
albumin quotient/IgG quotient, OCB oligoclonal bands, AQP4-IgG quotient CSF/serum AQP4-IgG
aFACS AQP4-IgG binding ratio for AQP4-M23
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